Skip to content

BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens

BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens: A Two Week Crossover Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02196766
Enrollment
30
Registered
2014-07-22
Start date
2014-07-31
Completion date
2014-08-31
Last updated
2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

To determine if patients are unreactive to the lens care solution / Biofinity combination.

Detailed description

To determine if patients are unreactive to the lens care solution / Biofinity combination in this cross-over study.

Interventions

OTHERBioclean First Care EX / comfilcon A

Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.

OTHERAosept Clearcare / comfilcon A

Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.

Sponsors

CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Is over 18 years of age (inclusive) * Has had a self-reported visual exam in the last two years * Is currently an adapted spherical soft CL wearer * Has a CL spherical prescription between - 0.25 and - 12.00 (inclusive) * Has less than 1.00D spectacle cylinder in each eye. * Is correctable to a visual acuity of 20/20 or better in both eyes * Has clear corneas and no active ocular disease * Has read, understood and signed the information consent letter. * Is willing to comply with the wear schedule (at least 40 hrs per week) * Is willing to comply with the visit schedule

Exclusion criteria

* Has never worn contact lenses before. * Currently wears rigid gas permeable contact lenses. * Has a history of not achieving comfortable CL wear (5 days per week; \> 8 hours/day) * Has a CL prescription outside the range of - 0.25 to -12.00D * Has a spectacle cylinder greater than -0.75D of cylinder in either eye. * Has best corrected spectacle distance vision worse than 20/20 in either eye. * Has any systemic disease affecting ocular health. * Is using any systemic or topical medications that will affect ocular health. * Has any ocular pathology or severe insufficiency of lacrimal secretion * Has persistent, clinically significant corneal or conjunctival staining * Has active neovascularization or any central corneal scars. * Is aphakic. * Is pregnant or lactating. * Has undergone corneal refractive surgery. * Is participating in any other type of eye related clinical or research study.

Design outcomes

Primary

MeasureTime frameDescription
Ocular Health - Corneal Staining1 weekCorneal staining for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).
Ocular Health - Conjunctival Redness1 weekConjunctival redness for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).
Ocular Health - Limbal Redness1 weekLimbal redness for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).
Ocular Health - Papillary Conjunctivitis1 weekPapillary conjunctivitis for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).

Secondary

MeasureTime frameDescription
Stinging Sensation Right After Insertion (Subjective Rating)BaselineSubjective rating of stinging sensation for the combinations is assessed at baseline. (Scale 0-10; 0=difficult to wear, 10=no sensation at all).
Burning Sensation Right After Insertion (Subjective Rating)BaselineSubjective rating of burning sensation right after insertion for each combination assessed at baseline. (Scale 0-10; 0=difficult to wear, 10=no sensation at all).

Countries

Japan

Participant flow

Participants by arm

ArmCount
Bioclean First Care EX / Aosept Clearcare / Comfil
Subjects dispensed either Bioclean First Care EX / comfilcon A combination or Aosept Clearcare / comfilcon A combination and then crossover to the alternate combination.
30
Total30

Baseline characteristics

CharacteristicBioclean First Care EX / Aosept Clearcare / Comfil
Age, Continuous31 years
STANDARD_DEVIATION 7.4
Region of Enrollment
Japan
30 participants
Sex: Female, Male
Female
21 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 300 / 30
serious
Total, serious adverse events
0 / 300 / 30

Outcome results

Primary

Ocular Health - Conjunctival Redness

Conjunctival redness for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).

Time frame: 1 week

ArmMeasureGroupValue (NUMBER)
Bioclean First Care EX / Comfilcon AOcular Health - Conjunctival RednessTrace20 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Conjunctival RednessModerate0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Conjunctival RednessMild0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Conjunctival RednessSevere0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Conjunctival RednessNormal40 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Conjunctival RednessSevere0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Conjunctival RednessNormal40 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Conjunctival RednessTrace20 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Conjunctival RednessMild0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Conjunctival RednessModerate0 Eyes
Primary

Ocular Health - Corneal Staining

Corneal staining for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).

Time frame: 1 week

ArmMeasureGroupValue (NUMBER)
Bioclean First Care EX / Comfilcon AOcular Health - Corneal StainingTrace18 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Corneal StainingModerate0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Corneal StainingMild4 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Corneal StainingSevere0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Corneal StainingNormal38 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Corneal StainingSevere0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Corneal StainingNormal35 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Corneal StainingTrace20 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Corneal StainingMild5 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Corneal StainingModerate0 Eyes
Primary

Ocular Health - Limbal Redness

Limbal redness for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).

Time frame: 1 week

ArmMeasureGroupValue (NUMBER)
Bioclean First Care EX / Comfilcon AOcular Health - Limbal RednessNormal49 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Limbal RednessMild0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Limbal RednessTrace11 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Limbal RednessSevere0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Limbal RednessModerate0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Limbal RednessSevere0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Limbal RednessModerate0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Limbal RednessNormal47 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Limbal RednessTrace12 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Limbal RednessMild1 Eyes
Primary

Ocular Health - Papillary Conjunctivitis

Papillary conjunctivitis for each combination was assessed by slit lamp at 1 week. (Grade 0-4; 0=normal, 1=trace, 2=mild, 3=moderate, 4= severe).

Time frame: 1 week

ArmMeasureGroupValue (NUMBER)
Bioclean First Care EX / Comfilcon AOcular Health - Papillary ConjunctivitisTrace7 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Papillary ConjunctivitisModerate0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Papillary ConjunctivitisMild1 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Papillary ConjunctivitisSevere0 Eyes
Bioclean First Care EX / Comfilcon AOcular Health - Papillary ConjunctivitisNormal52 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Papillary ConjunctivitisSevere0 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Papillary ConjunctivitisNormal51 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Papillary ConjunctivitisTrace8 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Papillary ConjunctivitisMild1 Eyes
Aosept Clearcare / Comfilcon AOcular Health - Papillary ConjunctivitisModerate0 Eyes
Secondary

Burning Sensation Right After Insertion (Subjective Rating)

Subjective rating of burning sensation right after insertion for each combination assessed at baseline. (Scale 0-10; 0=difficult to wear, 10=no sensation at all).

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Bioclean First Care EX / Comfilcon ABurning Sensation Right After Insertion (Subjective Rating)9.5 units on a scaleStandard Deviation 1.1
Aosept Clearcare / Comfilcon ABurning Sensation Right After Insertion (Subjective Rating)9.4 units on a scaleStandard Deviation 1.2
Secondary

Stinging Sensation Right After Insertion (Subjective Rating)

Subjective rating of stinging sensation for the combinations is assessed at baseline. (Scale 0-10; 0=difficult to wear, 10=no sensation at all).

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Bioclean First Care EX / Comfilcon AStinging Sensation Right After Insertion (Subjective Rating)9.5 units on a scaleStandard Deviation 1.1
Aosept Clearcare / Comfilcon AStinging Sensation Right After Insertion (Subjective Rating)9.4 units on a scaleStandard Deviation 1.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026